Incyte (INCY) Stock Forecast & Price Target

Incyte is supported by a durable commercial base anchored by Jakafi, which benefits from growth in myelofibrosis, polycythemia vera, and graft-versus-host disease, while Opzelura gives the company a meaningful dermatology growth engine that could approach $0.9B in sales and help offset the 2028 patent cliff. Its fundamentals are further strengthened by a deep oncology and inflammation pipeline, particularly INCB161734 for KRAS G12D, where 33 of 48 previously untreated patients responded across chemo combinations and a 20% U.S. first-line share could support roughly $700M in annual sales. Near-term upside is also supported by Atebrioz, which should deliver about $205M to $225M of gross economics before milestones and royalties, while Incyte keeps low-capital, high-margin economics through royalties, milestones, and a leveraged commercial infrastructure.

Incyte is facing a fundamentally negative setup because Jakafi remains the core earnings driver while patent expiry in late 2028 and possible generic entry in 2029 create a looming erosion risk, making lifecycle extension critical but uncertain. Its attempts to “fragment” the myelofibrosis market with a BET inhibitor, a CALR-targeting antibody, and a JAK2 V617F inhibitor offer many shots on goal, but the bar is high amid risks of slower Jakafi use, pricing pressure, and new competition. The downside case is compounded by mixed pipeline visibility and the broader concern that clinical or regulatory setbacks, alongside poorer performance from earlier-stage assets, could leave the firm vulnerable despite its marketed portfolio.